Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial. Soliman H, Hogue D, Han H, Mooney B, et al. Nat Med 2023;29:450-457.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Soliman H, Hogue D, Han H, Mooney B, et al. Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial. Nat Med 2023;29:450-457.
PMID: 36759673